



MEDIRAD Online Meeting – Programme

21 September 2020, 9:00-18:00 CEST

9:00-9:10	1. Welcome and introduction	Elisabeth Cardis, Guy Frija
	Pillar 1: Improvement of organ dose estimation and registration in order to a) inform clinical practice, optimise doses and set recommendations and b) provide adequate dosimetry for clinical-epidemiological studies of effects of medical radiation	Moderator: Filip Vanhavere
	2. Dosimetry: Current research achievements and future directions	Rapporteur: Jérémie Dabin
9:10-9:30	2.1 CT patient dosimetry	John Damilakis
9:30-9:50	2.2 CT dose from PET/CT and SPECT/CT	Klaus Bacher
9:50-10:10	2.3 Interventional radiology	Mercè Ginjaume
10:10-10:30	2.4 Retrospective CT dose reconstruction for epidemiological studies	Isabelle Thierry-Chef, Roger Fontana
10:30-10:50	2.5 Definition of a database to incorporate dosimetry data (incl. OpenDose3D)	Bernard Gibaud, Joel Spaltenstein
10:50-11:05	2.6 Discussion Pillar 1	All
11:05-11:15	Coffee break	
	Pillar 2: Evaluation of the effects of medical exposures, focusing on the two major endpoints and exposure conditions of public health and clinical relevance	Moderator: Mark Pearce
	3. Clinical/epidemiological studies	Rapporteur: Daan Spoor
11:15-11:25	3.1 Logistics of running a multinational dosimetry study for radioiodine treatment of thyroid cancer	Lavinia Vija
11:25-11:35	3.2 Logistics and legal aspects of implementing a nested case-control study	Elisabeth Cardis
11:35-11:50	3.3 A prediction-model for acute coronary events after breast cancer radiotherapy: first results of BRACE study	Anne Crijns, Daan Spoor

11:50-12:05	3.4 Preliminary early effect assessment of EARLY-HEART study	Sophie Jacob
12:05-12:15	3.5 Discussion on clinical/epidemiological studies	All
12:15-12:50	Lunch break	
	Pillar 2 – cont.	Moderator: Mark Pearce
	4. Radiobiology	Rapporteur: Magy Sallam
12:50-13:10	4.1 Induction and repair of DNA double-strand breaks in PMBCs during radioiodine therapy: First in vivo and ex vivo results	Uta Eberlein
13:10-13:30	4.2 Preclinical and clinical identification of standard and innovative biomarkers of radiation-induced cardiovascular toxicity	Radia Tamarat
13:30-13:50	4.3 Markers of sensitivity to radiation induced cancer	Gemma Armengol
13:50-14:10	5. Discussion Pillar 2	
	Pillar 3: Development of science-based policy recommendations for decision-makers and practitioners for the effective protection of patients, workers and the general public	Moderator: Marc Benderitter
	6. Recommendation 1: Development of recommendations to promote standardised procedures for patient data repositories	Rapporteur: Naomi Clayton
14:10-14:25	6.1 OpenDose3D: an open source software for clinical dosimetry: presentation and preliminary validation - WP2/3 efforts to set up repositories	Manuel Bardiès
14:25-14:40	6.2 Imaging and dose biobanks: Opportunities and challenges in medical research	Osman Ratib
14:40-14:50	6.3 Discussion Recommendation 1	All
14:50-15:00	Coffee break	
	Pillar 3 – cont.	Moderator: Marc Benderitter
	7. Recommendation 2: Development of recommendations on patient RP towards the medical communities	Rapporteur: Maelle Canet
15:00-15:15	7.1 Paediatric CT scanning: lessons learnt from large cohort studies	Marie-Odile Bernier
15:15-15:30	7.2 Cardiotoxicity based on first results of BRACE and animal experiments	Rob Coppes

15:30-15:40	7.3 Discussion Recommendation 2	All
	8. Recommendation 3: Development of recommendations on patient and worker RP towards policy makers and competent authorities	Rapporteur: Melanie Fachet
15:40-15:50	8.1 “Shielding” of workers	Jérémie Dabin
15:50-16:00	8.2 Structured reporting templates	Peter Mildemberger
16:00-16:10	8.3 CT image quality evaluation	Christoph Hoeschen
16:10-16:20	8.4 Discussion Recommendation 3	All
	9. Recommendation 4: Development of recommendations on future RP research towards research communities	Rapporteur: Nathalie Impens
16:20-16:30	9.1 Clinical trials to investigate dosimetry-based personalised treatment	Markus Luster
16:30-16:40	9.2 Future directions of CT dosimetry for research and how artificial intelligence can provide support	John Damilakis
16:40-16:50	9.3 Future directions of epidemiological studies of low to moderate doses, and cancer and non-cancer effects	Isabelle Thierry-Chef
16:50-17:00	9.4 Future directions of radiotherapy and cardiotoxicity	Hans Langendijk
17:00-17:10	9.5 Discussion Recommendation 4	All
17:10-17:25	10. Methodology for elaborating the MEDIRAD final recommendations to be delivered to the European Commission	Jacques Repussard
17:25-17:55	11. Overall discussion, open issues, etc. (3min for each WP, followed by discussion/Q&A)	Moderator: Guy Frija
17:55-18:00	12. Closure and good-bye	Elisabeth Cardis, Guy Frija